Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for the tip Jess, what’s the allure ?
Oh yes we do
Huge news !,
I can’t say.....a little to immature for the board, but it rhymes with punt mart
You guys would be better off referring to him as CF, just sayin’
Good one Jes#!
We have nothing to worry about with AUPH
Agreed Xwav, great presentation
And here we are over 15....
And we’re just under 15, Cervelo, you filling in for biotech, the new board beeeoootch?
And to 15 on Monday
You tooTony
I haven’t checked in for a while, I think it’s finally time for COCP to pop
I’m in !
Well said Pete, Slim, grab your a55, SUVRF is coming to the U.S.!!
Good stratery Slim, you have a good weekend as well.
Nice, Jess......big volume today, double what we’ve seen all week.
Right on Zep, I own a lot of stocks, but none are more poised to at least double in the next month or two and I think doubling is extremely conservative.
For longs who actually listen to the conference calls, Green leaf is obviously on point - it’s no wonder the stock is up almost a buck since the London healthcare Conf, yesterday.. For people who think this is a shady Canadian company, their Rockville, MD office is located in close proximity to the FDA, National Institutes of Health and a host of other bioscience firms nearby. Aurinia currently operates two offices in Canada , one in Fort Washington, Pennsylvania and a new 30,000sq foot office in Rockville, MD “This follows the recent build-out of our commercial leadership team, as we move swiftly yet responsibly toward commercial readiness,” Aurinia President and Chief Executive
I’m salivating just thinking about it!
This is good
Elwood blues could not put it better Jess
Elwood: It's 106 miles to Chicago, we got a full tank of gas, half a pack of cigarettes, it's dark... and we're wearing sunglasses.
Jake: Hit it.
The call was the opposite, and the reason financials were down was associated with roll out costs.AUPH will be positioned to roll out in 3 weeks.Biotech researcher is the only one selling right now, pick up his shares cheap.
Exactly Zep, and as always, not good on earnings but good news on the rollout,
.They will ready in December in case of an early green light, it’s fking exciting this could pop in a month.
Anyone else on that call?
You and I will only get excited when Voclosporin is approved, but for analysts to get excited, AUPH needs a solid balance sheet and earnings reports have always been horrible with AUPH. We may only see a buck or two on earnings, but we may get more market exposure, which brings higher price targets......I think you get the point.Wainwright is the only semi reputable brokerage firm that lists AUPH as a buy currently.
I just heard on CNBC via operation WarpSpeed , Pfizer vaccine needs to be kept at -98 degrees Fahrenheit. Pfizer plans on making their own dry ice to ship it in and WILL NOT be using McKesson distributors “given their track record “
States don’t have freezers to hold the vaccines so it sounds like they plan on keeping the vaccine on dry ice until administered, and each state will get a determined amount and figure out storage methods......we will not see this vaccine in a Walgreens or CVS anytime soon.The GOAL is to get the nation immune by June.Pfizer will only use FedEx and UPS for transportation of the vaccines.
All of this is good news for SRNE.
Who’s buying before the earnings report?
Great point church, I totally agree, just depends how it plays out.I hope we hold out for approval and distribution, but a savvy big cap Pharma, would have tremendous leverage offering a price before FDA approval.I hope, when that happens, AUPH refrains.
I wouldn’t be surprised in a January BO.
I couldn’t agree Church
All good points Dia
I share your sediment politically Dom, but regarding SRNE, I’m more concerned about product getting to market, than who’s going to be the President.There is huge demand globally for an instant covid test, I want SRNE to be the lead contender.
For those of you on the call, Ed Arce with Wainwright was asking some really good questions and getting feedback from the AUPH brass. he just posted his PT to 28 yesterday.
I hear ya Slim, the call was extremely informative.they want to put AUDREY on hold and focus on the LN rollout which creates more revenue and focus.They also eluded , on at least two occasions that they were really excited about their earnings report next week (the 12th).With the rollout only 2 months away and a strong earnings report, I look at this as an extremely good buying level, let’s face it, we all know this stock will at least double, and that’s the worst case scenario.
For AUPH longs who got in on this for LN, this creates a great buying opportunity.
I’m on the conference call now
1-877-407-9170
Not good news, but AUDREY was just a bonus, the real contestant is voclosporin for LN.
Good find Don !